Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17489160 | 0.86 | GLS (0.75) | GLSKDM4EALDH1A1GLALMNA | |
| SCHEMBL9804004 | 0.84 | GLS (0.56) | GLSKDM4EALDH1A1GLALMNA | |
| SCHEMBL859902 | 0.82 | — | — | |
| SCHEMBL18157878 | 0.82 | GLS (0.69) | GLSKDM4EALDH1A1GLALMNA | |
| SCHEMBL29351434 | 0.81 | GLS (0.62) | GLSKDM4EALDH1A1GLALMNA | |
| SCHEMBL6114653 | 0.80 | GLS (0.67) | GLSKDM4EALDH1A1GLALMNA | |
| SCHEMBL19557911 | 0.79 | GLS (0.41) | GLSKDM4EALDH1A1GLALMNA | |
| SCHEMBL551485 | 0.78 | GLS (0.64) | GLSKDM4EALDH1A1GLALMNA | |
| SCHEMBL2845116 | 0.78 | GLS (0.64) | GLSKDM4EALDH1A1GLALMNA | |
| SCHEMBL621968 | 0.78 | GLS (0.64) | GLSKDM4EALDH1A1GLALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113582928-A | Amino-phenol-oxygen-group zinc complex containing (substituted) pyrazole ring and preparation method and application thereof | 华东理工大学 | 2021-11-02 | — | — | CN | claimed |
| CN-117615760-A | Extended dosage regimen for integrin inhibitors | 普利安特治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-115989235-A | Methods of treating respiratory diseases using amino acid compounds | 普利安特治疗公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-4146264-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11419869-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| EP-3952902-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113582928-A | Amino-phenol-oxygen-group zinc complex containing (substituted) pyrazole ring and preparation method and application thereof | 华东理工大学 | 2021-11-02 | — | — | CN | disclosed |
| EP-3761980-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| WO-2019173653-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2018149986-A1 | 2-(BICYCLO-HETEROARYL)-ISONICOTINIC DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2018-08-23 | — | — | WO | disclosed |
| CN-105339368-B | Imidazo [1,2 a] pyridine of 3 aryl substitution and application thereof | 拜耳制药股份公司 | 2017-08-15 | — | — | CN | disclosed |
| EP-0790241-A1 | COMPLEXONES WITH THE STRUCTURE OF N-2-(AZOL-1(2)-YL)ETHYLIMINODIACETIC ACIDS, SYNTHESIS, ANALYTICAL STUDY AND BIOLOGICAL APPLICATIONS | UNIVERSIDAD NACIONAL DE EDUCACION A DISTANCIA (ES) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11419869-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | GLS 960/4885KDM4E 3281/4885ALDH1A1 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.